Goldman Sachs Group Analysts Give Roche (ROG) a CHF 325 Price Target
Other research analysts also recently issued research reports about the company. set a CHF 203 target price on Roche and gave the company a sell rating in a report on Friday, October 20th. Baader Bank set a CHF 256 target price on Roche and gave the company a buy rating in a report on Tuesday, November 21st. Berenberg Bank set a CHF 260 target price on Roche and gave the company a neutral rating in a report on Tuesday, October 24th. UBS set a CHF 260 target price on Roche and gave the company a neutral rating in a report on Wednesday, December 6th. Finally, Deutsche Bank set a CHF 254 target price on Roche and gave the company a neutral rating in a report on Thursday, November 23rd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of CHF 261.84.
Roche (VTX:ROG) opened at CHF 244.10 on Wednesday. Roche has a 1-year low of CHF 226.10 and a 1-year high of CHF 273.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.